CBAK Energy Technology, Inc. (CBAT): Nasdaq/NYSE listing notice — CBAK Energy receives Nasdaq bid price deficiency notice; 180-day cure period until June 2025

CBAK Energy Technology, Inc.

Notice received Dec 26, 2024: closing bid below $1.00 for 30 consecutive business days through Dec 24.
Company has until June 24, 2025 to regain compliance by closing at $1.00+ for 10 consecutive days.
If not cured, may qualify for an additional 180-day grace period; otherwise delisting proceedings begin.
Stock continues trading on Nasdaq (CBAT) with no immediate effect on listing.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

CBAK Energy Technology, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

December 26, 2024, CBAK Energy Technology, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is currently not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of US$1.00 per share. Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on

View on SEC.gov

18 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

CBAK Energy Technology, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-113104

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.